KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Amortization of Deferred Charges (2023)

Biocryst Pharmaceuticals (BCRX) has disclosed Amortization of Deferred Charges for 6 consecutive years, with $8.1 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Amortization of Deferred Charges changed N/A year-over-year to $8.1 million, compared with a TTM value of $8.5 million through Dec 2023, changed N/A, and an annual FY2023 reading of $8.5 million, changed N/A over the prior year.
  • Amortization of Deferred Charges was $8.1 million for Q4 2023 at Biocryst Pharmaceuticals, up from $110000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $8.1 million in Q4 2023 and bottomed at $8.1 million in Q4 2023.